🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Pharma Mar S.A.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  2. Etrasimod Arginine Blue

    Pharma Mar S.A.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  3. Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue

    Pharma Mar S.A.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  4. Eylea 40 mg/mL solution for injection in a vial

    Pharma Mar S.A.

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  5. FAT EMULSIONS , Triheptanoin

    Pharma Mar S.A.

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  6. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Pharma Mar S.A.

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Fluticasone propionate,Salbutamol sulfate, ProAir® RespiClick®, ProAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  8. Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix

    Pharma Mar S.A.

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial

  9. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  10. Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém

    Pharma Mar S.A.

    Bacterial vaginosis

    phase 3 small molecule active

    1 trial

  11. GLUCOTHERA PLUS

    Pharma Mar S.A.

    End-stage Kidney Disease

    phase 3 small molecule active

    1 trial

  12. GTX-102, GTX/UX Diluent and Flush Solution

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  13. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Pharma Mar S.A.

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  14. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Pharma Mar S.A.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  15. HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.

    Pharma Mar S.A.

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  16. IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules

    Pharma Mar S.A.

    High Risk Chronic Lymphocytic Leukaemia

    phase 3 small molecule active

    1 trial

  17. IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji

    Pharma Mar S.A.

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  18. INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  19. INZ-701, INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  20. Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate

    Pharma Mar S.A.

    Growth Hormone Deficiency (GHD)

    phase 3 small molecule active

    1 trial

  21. Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  22. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  23. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Pharma Mar S.A.

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  24. Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada

    Pharma Mar S.A.

    Impetigo

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources